Liver Biomarkers Predict Mortality in Fontan Circulation Patients
A retrospective cohort study of 334 adults with Fontan circulation—a complex congenital heart defect—has demonstrated that non-invasive biomarkers of liver fibrosis are potent prognostic indicators. The research, published in *Heart*, analyzed FibroSURE scores, APRI, FIB-4, and MELD-XI against clinical outcomes over a median follow-up of 5.6 years. The findings revealed that elevated scores across all four biomarkers were significantly associated with an increased hazard of death or transplant. For instance, a FibroSURE score above 0.74 was linked to a more than fivefold increased hazard, underscoring the critical role of liver health in the long-term management of these patients.
Why it might matter to you: This study highlights the expanding clinical utility of serological liver function tests and fibrosis panels beyond traditional hepatology, directly intersecting with cardiac and transplant medicine. For laboratory professionals, it reinforces the importance of accurate biomarker reporting and the integration of multi-organ prognostic panels into comprehensive diagnostic algorithms. It presents a clear case for the strategic value of laboratory data in guiding complex, life-altering clinical decisions for patients with multi-system disease.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.